TRML Jun 2024 17.500 put
| Previous Close | 4.6800 |
| Open | 4.6800 |
| Bid | 2.0000 |
| Ask | 6.3000 |
| Strike | 17.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 4.6800 - 4.6800 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 108 |
GlobeNewswireTourmaline Bio to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference: Jefferies Global Healthcare Conference, New YorkCorporate PresentationThursday, June 6, 2024 at 2:30 pm ET A live webca
- GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in the first half of 2025 with potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases – – TRANQUILITY trial intended to provide evidence of TOUR006’s best-in-class potential for ASCVD, including the potential for quarterl
- GlobeNewswire
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – – Expanded Thyroid Eye Disease (TED) clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Completed underwritten follow-on public offering in January 2024, raising gross proceeds of $172.5 million – – Ended the quarter with $35
